Belite Bio (BLTE) said Monday it has priced an underwritten public offering of about 2.3 million American depositary shares at $154 each.
The company said it has also granted underwriters a 30-day option to purchase up to 340,909 additional depositary shares.
The company said it expects gross proceeds of about $350 million from the offering, which is expected to close about Wednesday.
The company said it plans to use net proceeds of the offering for general corporate purposes.